Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Casas Nebra

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
International Journal of Molecular Sciences|August 14, 2025
Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C TreatmentBenito Blanco Gómez, Francisco Javier Casas-Nebra, Daniel Pérez-Fentes, et al.
Archivos Espanoles De Urologia|December 5, 2009
[Inguinal ureteral hernia: a clinical case]Antón Zarraonandia Andraca, Angel Ríos Reboledo, Javier Casas Nebra, et al.
Nanomaterials (Basel, Switzerland)|September 28, 2021
Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MSBenito Blanco Gómez, Rubén López-Cortés, Francisco Javier Casas-Nebra, et al.
Archivos Espanoles De Urologia|November 5, 2011
[Impact of predictive models and decision making in prostate cancer: An integral debate]Francisco Gómez Veiga, Jose Ponce Díaz-Reixa, Sonia Pértega Díaz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 12, 2024
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of <sup>177</sup>Lu-PSMA-617 radioligand-therapy in prostate cancerOvidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, et al.
Future Oncology (London, England)|May 24, 2023
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysisJoan Carles, Rafael A Medina-Lopez, Javier Puente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 10, 2026
Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC studyJavier Puente, Rubén Campanario, David Marmolejo, et al.
Frontiers in Oncology|May 22, 2024
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancerUrbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 5, 2026
Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'Sergio Vázquez-Estévez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
International Journal of Molecular Sciences|August 14, 2025
Variations in Circulating Tumor Microenvironment-Associated Proteins in Non-Muscle Invasive Bladder Cancer Induced by Mitomycin C TreatmentBenito Blanco Gómez, Francisco Javier Casas-Nebra, Daniel Pérez-Fentes, et al.
Archivos Espanoles De Urologia|December 5, 2009
[Inguinal ureteral hernia: a clinical case]Antón Zarraonandia Andraca, Angel Ríos Reboledo, Javier Casas Nebra, et al.
Nanomaterials (Basel, Switzerland)|September 28, 2021
Detection of Circulating Serum Protein Biomarkers of Non-Muscle Invasive Bladder Cancer after Protein Corona-Silver Nanoparticles Analysis by SWATH-MSBenito Blanco Gómez, Rubén López-Cortés, Francisco Javier Casas-Nebra, et al.
Archivos Espanoles De Urologia|November 5, 2011
[Impact of predictive models and decision making in prostate cancer: An integral debate]Francisco Gómez Veiga, Jose Ponce Díaz-Reixa, Sonia Pértega Díaz, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|September 12, 2024
Recommendations from the Galician Oncological Society and the Galician Society of Nuclear Medicine for the use of <sup>177</sup>Lu-PSMA-617 radioligand-therapy in prostate cancerOvidio Fernández Calvo, José Muñoz Iglesias, Estephany Abou Jokh Casas, et al.
Future Oncology (London, England)|May 24, 2023
Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysisJoan Carles, Rafael A Medina-Lopez, Javier Puente, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|February 10, 2026
Treatment patterns in patients with castration-resistant prostate cancer who received darolutamide in the ARAMIS trial in Spain: PARASEC studyJavier Puente, Rubén Campanario, David Marmolejo, et al.
Frontiers in Oncology|May 22, 2024
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancerUrbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|June 5, 2026
Clinical advances and practice updates in genitourinary cancers: a 2025 review from the multidisciplinary Spanish 'Cambados annual meeting'Sergio Vázquez-Estévez, Martín Lázaro-Quintela, Daniel Pérez-Fentes, et al.
Pageof 1